233 related articles for article (PubMed ID: 23517011)
1. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
Hewings DS; Fedorov O; Filippakopoulos P; Martin S; Picaud S; Tumber A; Wells C; Olcina MM; Freeman K; Gill A; Ritchie AJ; Sheppard DW; Russell AJ; Hammond EM; Knapp S; Brennan PE; Conway SJ
J Med Chem; 2013 Apr; 56(8):3217-27. PubMed ID: 23517011
[TBL] [Abstract][Full Text] [Related]
2. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
[TBL] [Abstract][Full Text] [Related]
3. Biased multicomponent reactions to develop novel bromodomain inhibitors.
McKeown MR; Shaw DL; Fu H; Liu S; Xu X; Marineau JJ; Huang Y; Zhang X; Buckley DL; Kadam A; Zhang Z; Blacklow SC; Qi J; Zhang W; Bradner JE
J Med Chem; 2014 Nov; 57(21):9019-27. PubMed ID: 25314271
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
[TBL] [Abstract][Full Text] [Related]
5. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
6. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.
Yoo M; Park TH; Yoo M; Kim Y; Lee JY; Lee KM; Ryu SE; Lee BI; Jung KY; Park CH
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802888
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
Jennings LE; Schiedel M; Hewings DS; Picaud S; Laurin CMC; Bruno PA; Bluck JP; Scorah AR; See L; Reynolds JK; Moroglu M; Mistry IN; Hicks A; Guzanov P; Clayton J; Evans CNG; Stazi G; Biggin PC; Mapp AK; Hammond EM; Humphreys PG; Filippakopoulos P; Conway SJ
Bioorg Med Chem; 2018 Jul; 26(11):2937-2957. PubMed ID: 29776834
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.
Rong J; Feng ZZ; Shi YJ; Ren J; Xu Y; Wang NY; Xue Q; Liu KL; Zhou SY; Wei W; Yu LT
Bioorg Med Chem Lett; 2019 Oct; 29(19):126577. PubMed ID: 31421967
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
[TBL] [Abstract][Full Text] [Related]
13. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
[TBL] [Abstract][Full Text] [Related]
15. Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
Sperandio D; Aktoudianakis V; Babaoglu K; Chen X; Elbel K; Chin G; Corkey B; Du J; Jiang B; Kobayashi T; Mackman R; Martinez R; Yang H; Zablocki J; Kusam S; Jordan K; Webb H; Bates JG; Lad L; Mish M; Niedziela-Majka A; Metobo S; Sapre A; Hung M; Jin D; Fung W; Kan E; Eisenberg G; Larson N; Newby ZER; Lansdon E; Tay C; Neve RM; Shevick SL; Breckenridge DG
Bioorg Med Chem; 2019 Feb; 27(3):457-469. PubMed ID: 30606676
[TBL] [Abstract][Full Text] [Related]
16. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
Fedorov O; Lingard H; Wells C; Monteiro OP; Picaud S; Keates T; Yapp C; Philpott M; Martin SJ; Felletar I; Marsden BD; Filippakopoulos P; Müller S; Knapp S; Brennan PE
J Med Chem; 2014 Jan; 57(2):462-76. PubMed ID: 24313754
[TBL] [Abstract][Full Text] [Related]
17. Development of Dimethylisoxazole-Attached Imidazo[1,2-
Muthengi A; Wimalasena VK; Yosief HO; Bikowitz MJ; Sigua LH; Wang T; Li D; Gaieb Z; Dhawan G; Liu S; Erickson J; Amaro RE; Schönbrunn E; Qi J; Zhang W
J Med Chem; 2021 May; 64(9):5787-5801. PubMed ID: 33872011
[TBL] [Abstract][Full Text] [Related]
18. Discovery and lead identification of quinazoline-based BRD4 inhibitors.
Yang SM; Urban DJ; Yoshioka M; Strovel JW; Fletcher S; Wang AQ; Xu X; Shah P; Hu X; Hall MD; Jadhav A; Maloney DJ
Bioorg Med Chem Lett; 2018 Nov; 28(21):3483-3488. PubMed ID: 30268702
[TBL] [Abstract][Full Text] [Related]
19. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.
Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X
J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
